Valen­z­aBio's on­col­o­gy is­land of mis­fit toys snares $70M af­ter toil­ing be­hind the scenes for months

David Maizen­berg’s imag­i­na­tion sparked when he came across a mon­o­clon­al an­ti­body from Can­cer Re­search UK’s re­ject pile.

The CD19-tar­get­ing mAb, orig­i­nal­ly dis­cov­ered by Mer­ck Serono …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER